Opko Health Inc. (OPK)

Trade OPK now with
8/29/2019 9:51:03 AM OPKO Completes Pivotal Phase 3 Study For Somatrogon
7/1/2019 8:06:10 AM BioReference Laboratories Forms Strategic Collaboration With SOMOS To Improve Health Outcomes Of Underserved New Yorkers
2/5/2019 8:35:08 AM OPKO Health Reports Pricing Of Offering Of $200 Mln Convertible Senior Notes Due 2025
2/1/2019 8:09:52 AM OPKO Health Gets FDA Approval For Point-of-Care Sangia PSA Test With Claros 1 Analyzer
1/31/2019 9:17:01 PM OPKO Provides Update On Development Of OPK-88004, Selective Androgen Receptor Modulator
1/7/2019 6:04:24 AM OPKO Health Appoints Jon Cohen As Executive Chairman Of BioReference Laboratories
11/9/2018 4:57:55 PM OPKO Health Q3 Loss Per Share $0.05 Vs. $0.06 Last Year
9/11/2018 8:32:46 AM OPKO Comments On Continued Nasdaq Halt Of Trading Of Common Stock
9/7/2018 3:42:03 PM Nasdaq Halts OPKO Health
6/11/2018 8:08:59 AM OPKO Health Completes Enrollment In Phase 2b Study Of OPK88003 To Treat Type 2 Diabetes And Obesity
3/23/2018 8:01:41 AM OPKO Health Enrolls First Patient In Phase 2b Study Of OPK88003 To Treat Type 2 Diabetes